Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FEMY
FEMY logo

FEMY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Femasys Inc (FEMY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.040
1 Day change
-3.58%
52 Week Range
22.200
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Femasys Inc (FEMY) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show a bearish trend, there are no significant positive catalysts or trading signals, and the stock lacks recent news or financial data to support a compelling investment case. Given the investor's preference for long-term investments, it would be prudent to wait for clearer bullish signals or improved fundamentals before considering this stock.

Technical Analysis

The technical indicators for FEMY are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 22.671, and the moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the pivot at 5.14 and the nearest support at 3.906.

Positive Catalysts

  • NULL identified. There are no recent news events, no significant insider or hedge fund trading trends, and no congress trading data available.

Neutral/Negative Catalysts

  • The stock is in a bearish technical trend, with a 60% chance of further declines in the short term (-3.7% next day, -2.58% next week, -0.88% next month). Additionally, there is no recent news or financial data to support a positive outlook.

Financial Performance

No financial data available for analysis due to an error in the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is available for FEMY.

Wall Street analysts forecast FEMY stock price to rise
2 Analyst Rating
Wall Street analysts forecast FEMY stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.190
sliders
Low
3
Averages
4.75
High
6.5
Current: 4.190
sliders
Low
3
Averages
4.75
High
6.5
Lake Street
Ben Haynor
Buy
initiated
$1.50
AI Analysis
2026-03-03
Reason
Lake Street
Ben Haynor
Price Target
$1.50
AI Analysis
2026-03-03
initiated
Buy
Reason
Lake Street analyst Ben Haynor initiated coverage of Femasys with a Buy rating and $1.50 price target. FemBloc is the first and only non-surgical alternative that can be performed in an OB/GYN office without incisions, anesthesia, or permanent implants and the device has CE Mark clearance and is currently in a registration trial for PMA approval from the FDA, notes the analyst. The latest data suggests about 1.2M surgical sterilizations occur in the U.S. each year, so this could be "a multi-billion-dollar market for Femasys in the U.S. alone," depending on average selling prices, the analyst tells investors.
Laidlaw
Yale Jen
initiated
$6.50
2025-11-20
Reason
Laidlaw
Yale Jen
Price Target
$6.50
2025-11-20
initiated
Reason
Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FEMY
Unlock Now

People Also Watch